Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput.

Tytuł:
The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput.
Autorzy:
Davis SZ; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.; Molecular, Cell, and Systems Biology Department, University of California Riverside, Riverside, CA, USA.
Singh PP; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Vendrely KM; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Shoue DA; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Checkley LA; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
McDew-White M; Texas Biomedical Research Institute, San Antonio, TX, USA.
Button-Simons KA; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Cassady Z; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Sievert MAC; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Foster GJ; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Nosten FH; Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Mae Sot, Thailand.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford Old Road Campus, Oxford, UK.
Anderson TJC; Texas Biomedical Research Institute, San Antonio, TX, USA.
Ferdig MT; Eck Institute for Global Health, Dept. of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA. .
Źródło:
Malaria journal [Malar J] 2020 Jan 31; Vol. 19 (1), pp. 54. Date of Electronic Publication: 2020 Jan 31.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2002-
MeSH Terms:
Antimalarials/*pharmacology
Artemisinins/*pharmacology
Malaria, Falciparum/*diagnosis
Parasitemia/*diagnosis
Plasmodium falciparum/*isolation & purification
Benzothiazoles ; Diamines ; Drug Resistance ; Erythrocytes/parasitology ; Flow Cytometry ; Fluorescent Dyes ; Half-Life ; Humans ; Malaria, Falciparum/drug therapy ; Organic Chemicals ; Parasitemia/drug therapy ; Plasmodium falciparum/drug effects ; Povidone ; Quinolines ; Real-Time Polymerase Chain Reaction/methods ; Silicon Dioxide
References:
Malar J. 2017 May 12;16(1):195. (PMID: 28494763)
Genome Biol. 2017 Apr 28;18(1):78. (PMID: 28454557)
PLoS One. 2016 Oct 25;11(10):e0165358. (PMID: 27780272)
N Engl J Med. 2014 Jul 31;371(5):411-23. (PMID: 25075834)
Lancet Infect Dis. 2017 May;17(5):491-497. (PMID: 28161569)
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5157-62. (PMID: 23431146)
PLoS Genet. 2014 Jan;10(1):e1004085. (PMID: 24391526)
Trans R Soc Trop Med Hyg. 1984;78(5):622-4. (PMID: 6095494)
J Infect Dis. 2013 Jun 1;207(11):1655-63. (PMID: 23448727)
Lancet Infect Dis. 2012 Nov;12(11):851-8. (PMID: 22940027)
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12513-12518. (PMID: 30455312)
Malar J. 2016 Feb 17;15:94. (PMID: 26888201)
Lancet. 2012 May 26;379(9830):1960-6. (PMID: 22484134)
J Infect Dis. 2019 Aug 30;220(7):1178-1187. (PMID: 31075171)
Mol Biol Evol. 2015 Apr;32(4):1080-90. (PMID: 25534029)
N Engl J Med. 2018 Nov 15;379(20):1962-1964. (PMID: 30428283)
Sci Rep. 2016 Oct 03;6:33891. (PMID: 27694982)
Malar J. 2019 Aug 28;18(1):295. (PMID: 31462253)
Mol Biol Evol. 2017 Jan;34(1):131-144. (PMID: 28025270)
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520. (PMID: 28289193)
J Infect Dis. 2017 Sep 15;216(6):723-731. (PMID: 28934435)
PLoS Genet. 2017 Oct 27;13(10):e1007065. (PMID: 29077712)
N Engl J Med. 2009 Jul 30;361(5):455-67. (PMID: 19641202)
Malar J. 2011 Nov 10;10:339. (PMID: 22074219)
BMC Med. 2019 Jan 17;17(1):1. (PMID: 30651111)
Lancet Infect Dis. 2013 Dec;13(12):1043-9. (PMID: 24035558)
Antimicrob Agents Chemother. 2014 Aug;58(8):4938-40. (PMID: 24867976)
Grant Information:
P01 AI127338 United States AI NIAID NIH HHS; R37 AI048071 United States AI NIAID NIH HHS; AI127338 National Institute of Allergy and Infectious Diseases
Contributed Indexing:
Keywords: Artemisinin resistance; Ring-stage survival assay; kelch13
Substance Nomenclature:
0 (Antimalarials)
0 (Artemisinins)
0 (Benzothiazoles)
0 (Diamines)
0 (Fluorescent Dyes)
0 (Organic Chemicals)
0 (Quinolines)
163795-75-3 (SYBR Green I)
65455-52-9 (Percoll)
6A9O50735X (artenimol)
7631-86-9 (Silicon Dioxide)
9RMU91N5K2 (artemisinin)
FZ989GH94E (Povidone)
Entry Date(s):
Date Created: 20200202 Date Completed: 20201201 Latest Revision: 20211204
Update Code:
20240105
PubMed Central ID:
PMC6995136
DOI:
10.1186/s12936-020-3139-6
PMID:
32005233
Czasopismo naukowe
Background: Tracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for in vitro artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for in vivo resistance, patient clearance half-life post-artemisinin treatment. Here a modified RSA is presented, the extended Recovery Ring-stage Survival Assay (eRRSA), using 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives, including parasite isolates with and without kelch13 mutations.
Methods: Plasmodium falciparum cultures were synchronized with single layer Percoll during the schizont stage of the intraerythrocytic development cycle. Cultures were left to reinvade to early ring-stage and parasitaemia was quantified using flow cytometry. Cultures were diluted to 2% haematocrit and 0.5% parasitaemia in a 96-well plate to start the assay, allowing for increased throughput and decreased variability between biological replicates. Parasites were treated with 700 nM of dihydroartemisinin or 0.02% dimethyl sulfoxide (DMSO) for 6 h, washed three times in drug-free media, and incubated for 66 or 114 h, when samples were collected and frozen for PCR amplification. A SYBR Green-based quantitative PCR method was used to quantify the fold-change between treated and untreated samples.
Results: 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives were assayed using the eRRSA. Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample. A Spearman correlation of - 0.8393 between fold change and patient clearance half-life was identified in these 15 isolates from Southeast Asia, which is the strongest correlation reported to date.
Conclusions: eRRSA drastically increases the efficiency and accuracy of in vitro artemisinin resistance phenotyping compared to the traditional RSA, which paves the way for extensive in vitro phenotyping of hundreds of artemisinin resistant parasites.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies